Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Somnomed Limited ( (AU:SOM) ).
SomnoMed Limited has announced a change in the director’s interest, with Benjamin Gisz reducing his indirect shareholding in the company. The transaction involved the sale of 13,211,430 ordinary shares at $0.70 per share, resulting in Gisz holding 54,504,649 ordinary shares post-transaction. This change reflects a significant adjustment in the director’s investment, potentially impacting the company’s market perception and investor confidence.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$0.99 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
More about Somnomed Limited
SomnoMed Limited operates in the healthcare industry, focusing on providing medical devices for the treatment of sleep-related disorders. The company is known for its oral appliance therapy products, which are designed to assist patients with obstructive sleep apnea.
Average Trading Volume: 64,256
Technical Sentiment Signal: Hold
Current Market Cap: A$159.3M
For a thorough assessment of SOM stock, go to TipRanks’ Stock Analysis page.